SanegeneBio is revolutionizing RNAi-powered therapies for metabolic and autoimmune diseases through their Ligand and Enhancer Assisted (LEAD™) Technology.
Location: China
Employees: 51-200
Total raised: $110M
Investors 1
| Date | Name | Website |
| 17.12.2025 | SymBiosis | symbiosis.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.12.2025 | Series B | $110M | Tencent |
Mentions in press and media 6
| Date | Title | Description |
| 02.02.2026 | SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech | - SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech - SanegeneBio to receive $200 million upfront payment and will be eligible to receive development and commercialization milestone payments, totaling u... |
| 09.12.2025 | Tencent-backed SanegeneBio secures over $110m Series B | - |
| 08.11.2025 | SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly | -Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research a... |
| 04.12.2023 | Deals in brief: Igloo and Gravel secure funding, COP28 participants step up financial commitments, multiple China, India, and Middle East deals, and more | Igloo raises USD 36 million in pre-Series C funding The insurtech company has announced the completion of its pre-Series C funding round, raising USD 36 million. The round was led by Eurazeo, utilizing its BNP Paribas Cardif-backed insurtec... |
| - | Under pressure, biotech and pharma grapple with how to take climate action | As the health impacts of climate change become harder to ignore, biotechnology and pharmaceutical companies are facing increasing pressure from investors, employees, and government regulators to reduce their carbon emissions, and to make en... |
| - | Sanegene Bio | “SanegeneBio is an emerging RNAi-based company developing innovative RNA interference (RNAi) therapeutics driven by the cutting-edge delivery technology. Founded in 2021, SanegeneBio was propelled by a team of industry-leading experts and h... |